-- Reports Exceptional Data from Sample Preparation with FFPE and Saliva Samples to Streamline NGS Workflows --
-- Adds Mitochondrial Custom Panel --
SAN FRANCISCO--(BUSINESS WIRE)--Oct. 16, 2019--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer, company and collaborator data using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS). In addition, Twist Bioscience will showcase the results of adding formalin-fixed paraffin-embedded (FFPE) and saliva sample preparation workflows with its NGS products, resulting in uniform sequence coverage of the target area of interest within the genome.
Researchers from Children’s Hospital Los Angeles and Weill Cornell Medicine to Share Data
In a company-sponsored workshop today, D. Gigi Ostrow, Ph.D., translational genomics manager for Children’s Hospital of Los Angeles will present “Our Twist on Cancer Predisposition Testing”, Duane C. Hassane, Ph.D., assistant professor of computational biomedicine in medicine at Weill Cornell Medical College, will present “From Pre-AML to Pre-CISE-1: Clonal Hematopoiesis, Acute Myeloid Leukemia and Molecular Aging”, and David Kupec of Twist Bioscience will provide an NGS tools product overview. Presentations will be available on the Resource section of the Twist Bioscience website.
Addition of Sample Preparation Solutions to Enhance Streamlined Workflow, New Mitochondrial Panel
The company also released new data combining sample preparation solutions integrated with the Twist Bioscience library preparation and target enrichment workflow, as well as a new fixed custom panel to conduct target enrichment of the mitochondrial DNA.
FFPE Sample Preparation Combined with Twist Solution
Library construction for NGS using FFPE samples offers unique challenges in acquiring high-quality sequencing data due to wide distribution of sample quality. Differences in formalin fixation methods, storage conditions, and age lead to crosslinked and/or degraded nucleic acid and inconsistent extraction yields. Therefore, FFPE extraction and library construction methods must be carefully considered for target enrichment applications. In collaboration, Covaris and Twist Bioscience demonstrate a complete library preparation and target enrichment solution that generates ready-to-sequence multiplexed libraries directly from FFPE tissue of various qualities. Specifically, the truXTRAC kit and adaptive focused acoustics (AFA) technology from Covaris generate size specific DNA libraries from FFPE samples that, when paired with Twist Bioscience’s Library Preparation and Human Core Exome Kit, deliver multiplexed libraries for high performance targeted sequencing.
Saliva Sample Preparation Combined with Twist Solution
The drive towards personalized medicine, pharmacogenomic testing and growth in the direct-to-consumer market has increased the number of genomic samples collected and analyzed year over year, with genomic laboratories now challenged to process more samples, more efficiently. Routine handling, such as DNA extraction, quantification and normalization, adds considerable time and cost to the laboratory workflow, often limiting the number of samples that can be processed in a single day. Twist reported results from an augmented method of using its Fast Hybridization & Wash Kit to rapidly sequence saliva samples in combination with DNA Genotek, allowing researchers to move from sample to sequencer in an eight-hour workday.
New Product Introduction: Twist Mitochondrial DNA Panel
Mitochondria are double-membrane-bound organelles found in most eukaryotic organisms. Commonly termed the “powerhouse” of the cell, mitochondria are responsible for creating the vast majority of the energy needed to sustain life and support organ function. When mitochondria fail to produce enough energy for the body to function as it should, mitochondrial disease results. Often chronic, genetic, and often inherited disorders, the Cleveland Clinic estimates that approximately one in 5,000 individuals is affected with a mitochondrial disease. Clinicians use familial history and genetic tests to aid in the diagnosis of mitochondrial disorders. At Twist Bioscience, we are working with top clinicians to provide answers for their patients with hard to diagnosis diseases. The Twist Mitochondrial Panel is a fixed content panel that covers 16kb and 37 genes of the human mitochondrial genome. The mitochondrial panel can be sequenced as a standalone panel or can be combined with the Twist Human Core Exome panel, leading to more comprehensive profiling for complex inherited disease studies.
“We are thrilled to see our products truly making a difference in the way research is conducted – from pediatric to oncology applications – and look forward to continuing our commitment to improve healthcare through improved synthetic DNA-based products,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By expanding our product line for compatibility with additional sample preparation options to enhance the workflow, we look forward to meeting additional needs for our customers and even allowing them to ‘Sequence the Unsequenceable’.”
Data using these new tools will be presented in the exhibit hall during ASHG and available through the Resources section of the Twist Bioscience website:
-
Poster #2596Y: Unique Dual Indexing Primers and Universal Blockers Enable Multiplexed Target Enrichment Applications will be presented by Kristin Butcher from 3:00 to 4:00 p.m. local time on Thursday, October 17
-
Poster #1850F: High Performance Multiplexed Target Enrichment Sequencing from FFPE Tissues will be presented by Richard Gantt from 2:00 to 3:00 p.m. local time on Friday, October 18.
-
Twist Bioscience will also host Booth 515
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
All Twist Bioscience products are Research Use Only.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2019. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005291/en/
Source: Twist Bioscience Corporation
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com
